Background: Although optimal medical management of acute severe ulcerative colitis (UC) is ill-defined, infliximab has become a standard of care. Accumulating evidence suggests an increased rate of infliximab clearance in patients with acute severe UC and a reduced colectomy rate with an intensified infliximab induction regimen.


Antibodies, Colectomy, Drug Therapy, Infliximab, Monoclonal, therapeutic use, Treatment Outcome, Ulcerative Colitis

Read More